Dr John Apostolopoulos presents at ADC 2024
D.T.R.G’s research scholarship recipient and research fellow Dr John Apostolopoulos presented two posters at the Australasian Diabetes Congress 2024. John presented on the Regent study and the MEWS study.
The Regent study investigated the feasibility of a novel treatment for type 2 diabetes using a non surgical, day procedure called duodenal mucosal re-celluarization. This procedure aims to regenerate the cells that help to regulate blood sugar in the duodenum, an area at the beginning on the small intestine. The results demonstrated that participants experienced a significant improvement in glycaemic control and a significant decrease in HbA1C.
The MEWs study evaluated a novel extended wear sensor designed by Medtronic which used the anti-inflammatory drug dexamethasone to increase the sensor’s lifespan and reliability of the sensor’s readings. Participants in this study wore the new sensor over 17 days. The results found that dexamethasone use was both feasible and safe for extending the life of the sensor, and that sensor integrity was maintained up to 17 days post insertion.
Dr John Apostolopoulos presents at ADC 2024
D.T.R.G’s research scholarship recipient and research fellow Dr John Apostolopoulos presented two posters at the Australasian Diabetes Congress 2024. John presented on the Regent study and the MEWS study.
The Regent study investigated the feasibility of a novel treatment for type 2 diabetes using a non surgical, day procedure called duodenal mucosal re-celluarization. This procedure aims to regenerate the cells that help to regulate blood sugar in the duodenum, an area at the beginning on the small intestine. The results demonstrated that participants experienced a significant improvement in glycaemic control and a significant decrease in HbA1C.
The MEWs study evaluated a novel extended wear sensor designed by Medtronic which used the anti-inflammatory drug dexamethasone to increase the sensor’s lifespan and reliability of the sensor’s readings. Participants in this study wore the new sensor over 17 days. The results found that dexamethasone use was both feasible and safe for extending the life of the sensor, and that sensor integrity was maintained up to 17 days post insertion.